Chris Furman serves as Chief Executive Officer and Director of Vitro Biopharma, a leading biotechnology company advancing regenerative medicine and cellular therapies for autoimmune, neurodegenerative, and inflammatory diseases. With over 25 years of executive experience in private and public capital markets, Mr. Furman brings a unique perspective to the biotech sector—one that bridges breakthrough science with disciplined investment strategy and global scalability.

Since assuming leadership of Vitro Biopharma in July 2022, Mr. Furman has spearheaded the company’s transformation into a globally connected research and clinical development partner. Leveraging his extensive financial background—including senior roles at Janus Capital Group, ArrowMark Partners, and Forum Capital Advisors—he has architected a comprehensive global partnership initiative that now spans four continents. This initiative has enabled Vitro Biopharma to collaborate with leading hospitals and medical research institutions on clinical trials and translational research, accelerating the path from discovery to patient care.

Mr. Furman holds a degree from the University of Pittsburgh and has earned certifications from Wharton Online (Fintech: Foundations and Applications of Financial Technology) and the Pepperdine Graziadio Business School (Private Capital Markets). His strategic leadership is rooted in a mission to align financial stewardship with scientific innovation—unlocking new therapeutic potential while expanding access to cutting-edge treatments worldwide.

At this conference, Mr. Furman will share his vision for how strategic capital, cross-border collaboration, and clinical infrastructure can converge to shape the future of regenerative medicine